Skip to content

Revolution Medicines

US · RVMD #499 by market cap Listed 2020
161.20 +1.77 +1.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 161.36 +1.21%
After-hours 165.32 +2.56%
Overnight 158.07 -0.85%
221.15144.19161.202026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RVMD?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +53.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days B → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -4,207.1% Better than 1%
Net margin -3,768.3% Better than 2%
Return on equity -58.1% Better than 8%
Return on invested capital -57.2% Better than 5%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -23.0% Better than 26%
6-month return 6.4% Better than 67%
12-month return (ex latest month) 163.8% Better than 98%
Distance below 52-week high 28.1% Better than 45%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 7.1x Better than 91%
Debt to assets 6.7% Better than 75%
Interest coverage -45.7x Better than 7%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 95.7% Better than 77%
Upside to average target 66.4% Better than 75%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -6.44%
1M -17.99%
3M -23.87%
6M +7.23%
YTD +102.39%
1Y +130.68%
3Y +641.83%
5Y +441.85%

Key statistics

Price & volume

Prev close
159.43
Open
161.61
Day range
160.22 - 169.51
Avg price
163.11
Volume
4.74M
Turnover
773.48M
Amplitude
5.83%
52-week range
71.15 - 224.31

Valuation

P/E
-27.09
P/E (TTM)
-17.66
P/B
14.52
EPS
-5.95
Net profit
-1.29B
Net assets
2.40B

Share structure

Market cap
34.87B
Float cap
31.94B
Shares out
216.29M
Float shares
198.15M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-02-13
52-week range 59% of range
71.15 224.31

28.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-16.21M net over the window

Short interest

Shares short
13.08M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Revolution Medicines (RVMD)?

Revolution Medicines last traded at 161.20. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Revolution Medicines's market cap?

About 34.87B.

What is the P/E ratio of Revolution Medicines?

The trailing twelve-month P/E is -17.66. The Valuation tab shows it against the stock's own five-year range.

Does Revolution Medicines pay a dividend?

Revolution Medicines does not currently pay a regular dividend.

Is Revolution Medicines a buy according to analysts?

The consensus of 23 analysts is a Buy rating, with an average 12-month price target of 268.26, which implies 66.4% upside from the current price. This is not investment advice.

What is Revolution Medicines's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Revolution Medicines a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Revolution Medicines discussion 0 comments

Add a comment